NASDAQ CM
NWBO

Northwest Biotherapeutics, Inc.

Shareholder Securities Fraud Litigation

Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Northwest Biotherapeutics, Inc. (NASDAQ CM: NWBO)

Rigrodsky & Long, P.A. announces that a complaint has been filed in the United States District Court for the District of Maryland on behalf of all persons or entities that purchased the common stock of Northwest Biotherapeutics, Inc. (“Northwest Biotherapeutics” or the “Company”) (NASDAQ CM: NWBO) between March 8, 2013 and August 20, 2015, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).

If you purchased shares of Northwest Biotherapeutics during the Class Period, or purchased shares prior to the Class Period and still hold Northwest Biotherapeutics, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to info@rl-legal.com.

The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects.  As a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.

According to the Complaint, on August 21, 2015, pre-market, news broke that the Company’s Phase 3 DCVax-L brain cancer treatment clinical trial in Germany was temporarily suspended.  Later on the same day, the Company stated that new screening of patient candidates for the trial had been temporarily suspended while the Company submitted certain information from the trial for regulatory review.

On this news, shares in Northwest Biotherapeutics dropped over 21%, closing at $6.96 per share on August 21, 2015, on heavy trading volume.

If you wish to serve as lead plaintiff, you must move the Court no later than October 26, 2015.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Attorney advertising.  Prior results do not guarantee a similar outcome.